Patients with breath test positive are necessary to be identified from irritable bowel syndrome: a c...
Patients with breath test positive are necessary to be identified from irritable bowel syndrome: a clinical trial based on microbiomics and rifaximin sensitivity
About this item
Full title
Author / Creator
Liu, Zuojing , Zhu, Shiwei , He, Meibo , Li, Mo , Wei, Hui , Zhang, Lu , Sun, Qinghua , Jia, Qiong , Hu, Nan , Fang, Yuan , Song, Lijin , Zhou, Chen , Tao, Heqing , Kao, John Y , Zhu, Huaiqiu , Owyang, Chung and Duan, Liping
Publisher
China: Lippincott Williams & Wilkins
Journal title
Language
English
Formats
Publication information
Publisher
China: Lippincott Williams & Wilkins
Subjects
More information
Scope and Contents
Contents
As a non-invasive and effective diagnostic method for small intestinal bacterial overgrowth (SIBO), wild-use of breath test (BT) has demonstrated a high comorbidity rate in patients with diarrhea-predominant irritable bowel syndrome (IBS-D) and SIBO. Patients overlapping with SIBO respond better to rifaximin therapy than those with IBS-D only. Gut...
Alternative Titles
Full title
Patients with breath test positive are necessary to be identified from irritable bowel syndrome: a clinical trial based on microbiomics and rifaximin sensitivity
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_6d49a1cd7510453095cd0c2501b4d888
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_6d49a1cd7510453095cd0c2501b4d888
Other Identifiers
ISSN
0366-6999
E-ISSN
2542-5641
DOI
10.1097/CM9.0000000000002294
